跳转至内容
Merck
CN

J100037

乙醇钽(V)

electronic grade, ≥95%, ≥99.999% metals basis

别名:

Pentaethoxytantalum, Tantalum pentaethoxide

登录 查看组织和合同定价。

选择尺寸

变更视图

关于此项目

线性分子式:
Ta(OC2H5)5
化学文摘社编号:
分子量:
406.25
EC Number:
228-010-2
MDL number:
Beilstein/REAXYS Number:
3678999
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助


grade

electronic grade

description

J100037

assay

≥95%, ≥99.999% metals basis

form

liquid

refractive index

n20/D 1.487 (lit.)

bp

155 °C/0.01 mmHg

mp

21 °C

density

1.566 g/mL at 25 °C

SMILES string

CCO[Ta](OCC)(OCC)(OCC)OCC

InChI

1S/5C2H5O.Ta/c5*1-2-3;/h5*2H2,1H3;/q5*-1;+5

InChI key

HSXKFDGTKKAEHL-UHFFFAOYSA-N

General description

请咨询数量、价格和包装选择信息。


Still not finding the right product?

Explore all of our products under 乙醇钽(V)


pictograms

Flame

signalword

Warning

hcodes

Hazard Classifications

Flam. Liq. 3

存储类别

3 - Flammable liquids

wgk

WGK 1

flash_point_f

84.2 °F - closed cup

flash_point_c

29 °C - closed cup

ppe

Faceshields, Gloves, Goggles, type ABEK (EN14387) respirator filter



历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

没有发现合适的版本?

如果您需要特殊版本,可通过批号或批次号查找具体证书。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库



Catharina M L Zegers et al.
Clinical cancer research : an official journal of the American Association for Cancer Research, 20(24), 6389-6397 (2014-10-16)
Increased tumor metabolism and hypoxia are related to poor prognosis in solid tumors, including non-small cell lung cancer (NSCLC). PET imaging is a noninvasive technique that is frequently used to visualize and quantify tumor metabolism and hypoxia. The aim of
I A Elsum et al.
Oncogene, 33(48), 5523-5533 (2013-11-28)
Lung cancer is the leading cause of cancer deaths worldwide with non small-cell lung cancer (NSCLC) accounting for 80% of all lung cancers. Although activating mutations in genes of the RAS-MAPK pathway occur in up to 30% of all NSCLC
Martina Weineisen et al.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 56(8), 1169-1176 (2015-06-20)
On the basis of the high and consistent expression of prostate-specific membrane antigen (PSMA) in metastatic prostate cancer (PC), the goal of this study was the development, preclinical evaluation, and first proof-of-concept investigation of a PSMA inhibitor for imaging and